{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:08Z","timestamp":1792197248825,"version":"4.4.0"},"reference-count":44,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","award":["397234"],"award-info":[{"award-number":["397234"]}],"id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2020,4,24]]},"abstract":"<jats:sec>\n<jats:title>BACKGROUND:<\/jats:title>\n<jats:p>The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil\n(5-FU). Nitroxoline (NIT), a potent inhibitor of Cathepsin B, impairs tumor progression by decreased extracellular\nmatrix degradation. The objective of the current project was designed to target nanoparticles for co-delivery\nof 5-FU and NIT in order to enhance the 5-FU cytotoxic effects and reduce the metastatic properties of HepG2\ncells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS:<\/jats:title>\n<jats:p>5-FU and NIT were loaded in chitosan-chondroitin nanoparticles. To target the CD44 receptors of\nHepG2 cells, Hyaluronic Acid (HA) was conjugated to the chondroitin by adipic acid dihydrazide and the conjugation\nwas confirmed by FTIR and 1HNMR. After physicochemical characterization and optimization of the\nprocessing variables, MTT assay was done on HepG2 and NIH3T3 cell lines to determine the cytotoxic properties\nof HA targeted nanoparticles. Migration of the cells was studied to compare the co-delivery of the drugs\nwith each drug alone.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS:<\/jats:title>\n<jats:p>The optimized nanoparticles showed the particle size of 244.7\u00b116.3nm, PDI of 0.30\u00b10.03, drug entrapment\nefficiency of 46.3\u00b15.0% for 5-FU and 75.1\u00b10.9% for NIT. The drug release efficiency up to 8 hours\nwas about 37.6\u00b10.9% for 5-FU and 62.9\u00b10.7% for NIT. The co-delivery of 5-FU and NIT in targeted nanoparticles\nshowed significantly more cytotoxicity than the mixture of the two free drugs, non-targeted nanoparticles or\neach drug alone and reduced the IC50 value of 5-FU from 3.31\u00b10.65\u03bcg\/ml to 0.17\u00b10.03\u03bcg\/ml and the migration\nof HepG2 cells was also reduced to five-fold.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CONCLUSION:<\/jats:title>\n<jats:p>Co-delivery of 5-FU and NIT by HA targeted chitosan-chondroitin nanoparticles may be promising\nin HCC.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520619666190930124746","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T11:45:31Z","timestamp":1569843931000},"page":"346-358","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5798","authenticated-orcid":true,"given":"Jaleh","family":"Varshosaz","sequence":"first","affiliation":[{"name":"Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monireh M.","family":"Fard","sequence":"additional","affiliation":[{"name":"Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Mirian","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshid","family":"Hassanzadeh","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5009\/gnl15257","volume":"10","author":"Zhu R.X.","year":"2016","unstructured":"Zhu R.X.; Seto W.K.; Lai C.L.; Yuen M.F.; Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver 2016,10(3),332-339","journal-title":"Gut Liver"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3892\/ijo.2011.1300","volume":"40","author":"Uchibori K.","year":"2012","unstructured":"Uchibori K.; Kasamatsu A.; Sunaga M.; Yokota S.; Sakurada T.; Kobayashi E.; Yoshikawa M.; Uzawa K.; Ueda S.; Tanzawa H.; Sato N.; Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol 2012,40(4),1005-1010","journal-title":"Int J Oncol"},{"key":"ref=3","first-page":"417","volume":"6","author":"Lampe C.M.","year":"2014","unstructured":"Lampe C.M.; Gondi C.S.; Cathepsin B inhibitors for targeted cancer therapy. J Cancer Sci Ther 2014,6,417-421","journal-title":"J Cancer Sci Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0009-8981(99)00224-7","volume":"291","author":"Koblinski J.E.","year":"2000","unstructured":"Koblinski J.E.; Ahram M.; Sloane B.F.; Unraveling the role of proteases in cancer. Clin Chim Acta 2000,291(2),113-135","journal-title":"Clin Chim Acta"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1042\/bj2820273","volume":"282","author":"Buck M.R.","year":"1992","unstructured":"Buck M.R.; Karustis D.G.; Day N.A.; Honn K.V.; Sloane B.F.; Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 1992,282(Pt 1),273-278","journal-title":"Biochem J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12943-016-0503-9","volume":"15","author":"Ruan J.","year":"2016","unstructured":"Ruan J.; Zheng H.; Rong X.; Rong X.; Zhang J.; Fang W.; Zhao P.; Luo R.; Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Mol Cancer 2016,15(1),17","journal-title":"Mol Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.3892\/ol.2016.4380","volume":"11","author":"Zhang Q.I.","year":"2016","unstructured":"Zhang Q.I.; Wang S.; Yang D.; Pan K.; Li L.; Yuan S.; Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing. Oncol Lett 2016,11(5),3265-3272","journal-title":"Oncol Lett"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/jnci\/djq457","volume":"102","author":"Shim J.S.","year":"2010","unstructured":"Shim J.S.; Matsui Y.; Bhat S.; Nacev B.A.; Xu J.; Bhang H.E.; Dhara S.; Han K.C.; Chong C.R.; Pomper M.G.; So A.; Liu J.O.; Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst 2010,102(24),1855-1873","journal-title":"J Natl Cancer Inst"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/neuonc\/nou139","volume":"17","author":"Lazovic J.","year":"2015","unstructured":"Lazovic J.; Guo L.; Nakashima J.; Mirsadraei L.; Yong W.; Kim H.J.; Ellingson B.; Wu H.; Pope W.B.; Nitroxoline induces apoptosis and slows glioma growth in vivo. Neuro-oncol 2015,17(1),53-62","journal-title":"Neuro-oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"19027","DOI":"10.18632\/oncotarget.3699","volume":"6","author":"Mirkovi\u0107 B.","year":"2015","unstructured":"Mirkovi\u0107 B.; Markelc B.; Butinar M.; Mitrovi\u0107 A.; Sosi\u010d I.; Gobec S.; Vasiljeva O.; Turk B.; \u010cema\u017ear M.; Ser\u0161a G.; Kos J.; Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity. Oncotarget 2015,6(22),19027-19042","journal-title":"Oncotarget"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mabi.201300383","volume":"14","author":"Oommen O.P.","year":"2014","unstructured":"Oommen O.P.; Garousi J.; Sloff M.; Varghese O.P.; Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: an alternative to prodrug approach. Macromol Biosci 2014,14(3),327-333","journal-title":"Macromol Biosci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"7828","DOI":"10.18632\/oncotarget.3488","volume":"6","author":"Gao Y.","year":"2015","unstructured":"Gao Y.; Ruan B.; Liu W.; Wang J.; Yang X.; Zhang Z.; Li X.; Duan J.; Zhang F.; Ding R.; Tao K.; Dou K.; Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition. Oncotarget 2015,6(10),7828-7837","journal-title":"Oncotarget"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jop.12296","volume":"44","author":"Dong C.","year":"2015","unstructured":"Dong C.; Ye D.X.; Zhang W.B.; Pan H.Y.; Zhang Z.Y.; Zhang L.; Overexpression of c-fos promotes cell invasion and migration via CD44 pathway in oral squamous cell carcinoma. J Oral Pathol Med 2015,44(5),353-360","journal-title":"J Oral Pathol Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3109\/1061186X.2015.1052072","volume":"23","author":"Mattheolabakis G.","year":"2015","unstructured":"Mattheolabakis G.; Milane L.; Singh A.; Amiji M.M.; Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine. J Drug Target 2015,23(7-8),605-618","journal-title":"J Drug Target"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3390\/polym10101133","volume":"10","author":"Kim J.H.","year":"2018","unstructured":"Kim J.H.; Moon M.J.; Kim D.Y.; Heo S.H.; Jeong Y.Y.; Hyaluronic acid-based nanomaterials for cancer therapy. Polymers (Basel) 2018,10(10),1133","journal-title":"Polymers (Basel)"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.addr.2008.09.001","volume":"60","author":"Liu Z.","year":"2008","unstructured":"Liu Z.; Jiao Y.; Wang Y.; Zhou C.; Zhang Z.; Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 2008,60(15),1650-1662","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=17","first-page":"275","volume":"6","author":"Reddy K.","year":"2011","unstructured":"Reddy K.; Krishna Mohan G.; Satla S.; Gaikwad S.; Natural polysaccharides: Versatile excipients for controlled drug delivery systems. Asian J Pharm Sci 2011,6(6),275-286","journal-title":"Asian J Pharm Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.microc.2009.02.001","volume":"92","author":"Yang H.C.","year":"2009","unstructured":"Yang H.C.; Hon M.H.; The effect of the molecular weight of chitosan nanoparticles and its application on drug delivery. Microchem J 2009,92(1),87-91","journal-title":"Microchem J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2174\/1389557517666170228105731","volume":"17","author":"Kamath P.R.","year":"2017","unstructured":"Kamath P.R.; Sunil D.; Nano-chitosan particles in anticancer drug delivery: An up-to-date review. Mini Rev Med Chem 2017,17(15),1457-1487","journal-title":"Mini Rev Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1590\/S1984-82502013000100013","volume":"49","author":"Mattos A.C.D.","year":"2013","unstructured":"Mattos A.C.D.; Khalil N.M.; Mainardes R.M.; Development and validation of an HPLC method for the determination of fluorouracil in polymeric nanoparticles. Braz J Pharm Sci 2013,49(1),117-126","journal-title":"Braz J Pharm Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"26032","DOI":"10.18632\/oncotarget.25430","volume":"9","author":"Badawi M.","year":"2018","unstructured":"Badawi M.; Kim J.; Dauki A.; Sutaria D.; Motiwala T.; Reyes R.; Wani N.; Kolli S.; Jiang J.; Coss C.C.; Jacob S.T.; Phelps M.A.; Schmittgen T.D.; CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget 2018,9(40),26032-26045","journal-title":"Oncotarget"},{"key":"ref=22","first-page":"316","volume":"6","author":"Figueroa C.M.","year":"2015","unstructured":"Figueroa C.M.; Morales-Cruz M.; Su\u00e1rez B.N.; Fern\u00e1ndez J.C.; Molina A.M.; Qui\u00f1ones C.M.; Griebenow K.; Induction of cancer cell death by Hyaluronic acid-mediated uptake of Cytochrome c. J Nanomed Nanotechnol 2015,6(5),316","journal-title":"J Nanomed Nanotechnol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"51046","DOI":"10.3791\/51046","volume":"88","author":"Justus C.R.","year":"2014","unstructured":"Justus C.R.; Leffler N.; Ruiz-Echevarria M.; Yang L.V.; \n                        In vitro cell migration and invasion assays. J Vis Exp 2014,88(88),51046","journal-title":"J Vis Exp"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.carbpol.2011.03.045","volume":"85","author":"Li P.","year":"2011","unstructured":"Li P.; Wang Y.; Peng Z.; She F.; Kong L.; Development of chitosan nanoparticles as drug delivery systems for 5-fluorouracil and leucovorin blends. Carbohydr Polym 2011,85(3),698-704","journal-title":"Carbohydr Polym"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1208\/pt070250","volume":"7","author":"Bhumkar D.R.","year":"2006","unstructured":"Bhumkar D.R.; Pokharkar V.B.; Studies on effect of pH on cross-linking of chitosan with sodium tripolyphosphate: A technical note. AAPS PharmSciTech 2006,7(2)","journal-title":"AAPS PharmSciTech"},{"key":"ref=26","first-page":"109","volume":"3","author":"Ragavan B.C.V.","year":"2015","unstructured":"Ragavan B.C.V.; Tamilselvan N.; Karthick S.; Venkatanarayanan R.; Formulation and evaluation of 5 fluorouracil nanoparticles for the tratment of colorectal cancer. Asian J Res Biol Pharm Sci 2015,3(3),109-117","journal-title":"Asian J Res Biol Pharm Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.5301\/jabfm.5000278","volume":"14","author":"Kiaie N.","year":"2016","unstructured":"Kiaie N.; Aghdam R.M.; Tafti S.H.; Emami S.H.; Statistical optimization of chitosan nanoparticles as protein vehicles, using response surface methodology. J Appl Biomater Funct Mater 2016,14(4),e413-e422","journal-title":"J Appl Biomater Funct Mater"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1248\/cpb.59.272","volume":"59","author":"Nagarwal R.C.","year":"2011","unstructured":"Nagarwal R.C.; Singh P.N.; Kant S.; Maiti P.; Pandit J.K.; Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: Characterization, in vitro and in vivo study. Chem Pharm Bull (Tokyo) 2011,59(2),272-278","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/13880200600746246","volume":"44","author":"Deng Q.Y.","year":"2006","unstructured":"Deng Q.Y.; Zhou C.R.; Luo B.H.; Preparation and characterization of chitosan nanoparticles containing lysozyme. Pharm Biol 2006,44(5),336-342","journal-title":"Pharm Biol"},{"key":"ref=30","first-page":"155","volume":"8","author":"Raja Azalea D.","year":"2012","unstructured":"Raja Azalea D.; Mohambed M.; Joji S.; Sankar C.; Design and evaluation of chitosan nanoparticles as novel drug carriers for the delivery of donepezil. Iran J Pharm Sci 2012,8(3),155-164","journal-title":"Iran J Pharm Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"34974","DOI":"10.1021\/acsami.8b12812","volume":"10","author":"Hu D.","year":"2018","unstructured":"Hu D.; Xu H.; Xiao B.; Li D.; Zhou Z.; Liu X.; Tang J.; Shen Y.; Albumin-stabilized metal\u2013organic nanoparticles for effective delivery of metal complex anticancer drugs. ACS Appl Mater Interfaces 2018,10(41),34974-34982","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"9106","DOI":"10.1021\/bi1009503","volume":"49","author":"Somasunderam A.","year":"2010","unstructured":"Somasunderam A.; Thiviyanathan V.; Tanaka T.; Li X.; Neerathilingam M.; Lokesh G.L.R.; Mann A.; Peng Y.; Ferrari M.; Klostergaard J.; Gorenstein D.G.; Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry 2010,49(42),9106-9112","journal-title":"Biochemistry"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1016\/j.biomaterials.2013.12.095","volume":"35","author":"Li L.","year":"2014","unstructured":"Li L.; Gu W.; Chen J.; Chen W.; Xu Z.P.; Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles. Biomaterials 2014,35(10),3331-3339","journal-title":"Biomaterials"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12663-018-1126-z","volume":"17","author":"Srivastava S.","year":"2018","unstructured":"Srivastava S.; Mohammad S.; Pant A.B.; Mishra P.R.; Pandey G.; Gupta S.; Farooqui S.; Co-delivery of 5-fluorouracil and curcumin nanohybrid formulations for improved chemotherapy against oral squamous cell carcinoma. J Maxillofac Oral Surg 2018,17(4),597-610","journal-title":"J Maxillofac Oral Surg"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejpb.2014.04.017","volume":"88","author":"Anitha A.","year":"2014","unstructured":"Anitha A.; Sreeranganathan M.; Chennazhi K.P.; Lakshmanan V.K.; Jayakumar R.; \n                        In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies. Eur J Pharm Biopharm 2014,88(1),238-251","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=36","first-page":"437","volume":"9","author":"Balasubramanian S.","year":"2014","unstructured":"Balasubramanian S.; Girija A.R.; Nagaoka Y.; Iwai S.; Suzuki M.; Kizhikkilot V.; Yoshida Y.; Maekawa T.; Nair S.D.; Curcumin and 5-fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nanoformulation: A synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia. Int J Nanomedicine 2014,9,437-459","journal-title":"Int J Nanomedicine"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.xphs.2018.10.042","volume":"108","author":"Ni W.","year":"2019","unstructured":"Ni W.; Li Z.; Liu Z.; Ji Y.; Wu L.; Sun S.; Jian X.; Gao X.; Dual-targeting nanoparticles: Codelivery of curcumin and 5-fluorouracil for synergistic treatment of hepatocarcinoma. J Pharm Sci 2019,108(3),1284-1295","journal-title":"J Pharm Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"49509","DOI":"10.18632\/oncotarget.10375","volume":"7","author":"Ke M.","year":"2016","unstructured":"Ke M.; Wang H.; Zhou Y.; Li J.; Liu Y.; Zhang M.; Dou J.; Xi T.; Shen B.; Zhou C.; SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D\/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice. Oncotarget 2016,7(31),49509-49526","journal-title":"Oncotarget"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1159\/000485955","volume":"44","author":"Hu N.","year":"2017","unstructured":"Hu N.; Yin J.F.; Ji Z.; Hong Y.; Wu P.; Bian B.; Song Z.; Li R.; Liu Q.; Wu F.; Strengthening gastric cancer therapy by trastuzumab-conjugated nanoparticles with simultaneous encapsulation of anti-MiR-21 and 5-Fluorouridine. Cell Physiol Biochem 2017,44(6),2158-2173","journal-title":"Cell Physiol Biochem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s11671-018-2716-x","volume":"13","author":"Feng Y.","year":"2018","unstructured":"Feng Y.; Gao Y.; Wang D.; Xu Z.; Sun W.; Ren P.; Autophagy inhibitor (LY294002) and 5-fluorouracil (5-FU) combination-based nanoliposome for enhanced efficacy against esophageal squamous cell carcinoma. Nanoscale Res Lett 2018,13(1),325","journal-title":"Nanoscale Res Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.2147\/DDDT.S140797","volume":"11","author":"Gao Z.","year":"2017","unstructured":"Gao Z.; Li Z.; Yan J.; Wang P.; Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy. Drug Des Devel Ther 2017,11,2595-2604","journal-title":"Drug Des Devel Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7150\/ijbs.32259","volume":"15","author":"Xu N.","year":"2019","unstructured":"Xu N.; Huang L.; Li X.; Watanabe M.; Li C.; Xu A.; Liu C.; Li Q.; Araki M.; Wada K.; Nasu Y.; Huang P.; The novel combination of nitroxoline and PD-1 blockade, exerts a potent antitumor effect in a mouse model of prostate cancer. Int J Biol Sci 2019,15(5),919-928","journal-title":"Int J Biol Sci"},{"key":"ref=43","author":"Rebbaa A.","year":"2006","unstructured":"Rebbaa A.; Use of cathepsin inhibitors for reversing or preventing\nresistance of a cancer cell to a cytotoxic agent. WO Patent\n2006068742A2, 2006"},{"key":"ref=44","author":"Pan K.","year":"2019","unstructured":"Pan K.; Hoang P.; Lee C.; Use of the combination in the treatment\nof cancer with nitroxoline and its analogues, with chemotherapeutics\nand immunotherapeutics. JP Patent 2019510825A 2019"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T04:16:50Z","timestamp":1589861810000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175209\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520619666190930124746","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}